Cyclopharm Limited · ASX:CYC
Cyclopharm — Shareholder Meeting (May 2010)
29 slides from Cyclopharm's shareholder meeting presentation, May 20, 2010
Slide 1: Cyclopharm Limited Annual General Meeting 20 May 2010
For personal use only Cyclopharm Limited Annual General Meetingg 20 May 2010
Slide 2: Disclaimer
Disclaimer For personal use only Certain views expressed here contain information derived from publicly available sources that have not been independently verified. The presentation includes certain statements, estimates and projections with respect to the anticipated future financial performance of
Slide 3: Agenda
Agenda g For personal use only Chairman’s Address Managing Director’s Review Question Time Business Close 3
Slide 4: Chairman's Address
For personal use only Chairman’s Address Vanda Gould 4
Slide 5: Managing Director's Review
For personal use only Managing Director’s Review James McBrayer 5
Slide 6: Cyclopharm business
Cyclopharm business Three business units For personal use only Cyclopharm ‐ helping save lives everyday! Technegas Radiopharmaceuticals Diagnostic Imaging Established in 1986 continues to Establishment of PET central Developing centres that provide generate revenue, profits and strong pharmacies to
Slide 7: Highlights - Financial Year 2009
Highlights ‐ Financial Year 2009 For personal use only 9 Profits up 19% and EPS consistent 9 Revenues of $11m up 2% 9 Settlement of arbitration with Clinquest Inc resulting in receipt of US$1 8m US$1.8m 9 PET Nuclear pharmacy plan on track 9 Expansion into diagnostic imaging 9 FDA progressing p g g
Slide 8: Segmental Overview
For personal use only Segmental Overview 8
Slide 9: Technegas - Components of Technegas
Technegas g For personal use only Components of Technegas There are three components required for a Technegas procedure: 1. Generator 1. Technegas Generator 2. A single use Patient Administration 2. PAS Set (PAS) 3. A single use patient crucible All components are manufactured at Cyclopharm’s Austra
Slide 10: Technegas - Global footprint
Technegas Global footprint For personal use only • Technegas is sold in 55 countries across the world • Over 2,400,000 patient studies since 1986 • 163,000 patient studies conducted in 2009 • 1,100 Technegas generators sold globally North America, 16% America • Patents in 36 countries Asia Pacific,
Slide 11: Molecular Imaging - Positron Emission Tomography (PET)
Molecular Imaging ‐ Positron Emission Tomography (PET) For personal use only PET is the future of Nuclear Medicine. Positron Emission Tomography allows physicians to differentiate between healthy and active diseased tissue. P . ET is primarily used in the detection of cancer Oncology 93.7% Neurology
Slide 12: PET Radiopharmaceuticals - Uses beyond Oncology
PET Radiopharmaceuticals Uses beyond Oncology For personal use only Neurology ¾ Alzheimer's ¾ Schizophrenia ¾ Epilepsy p py ¾ Parkinson's ¾ Stroke ¾ Mood disorders, disorders ¾ Substance abuse Cardiology gy ¾ Myocardium viability Pharmacology ¾ Radio‐labeling drugs for biodistributon studies 12
Slide 13: Radiopharmaceuticals - PET Developments
Radiopharmaceuticals PET Developments For personal use only Government Funding • Six approved indications for PET • Another eight indications targeting Cancer are under review i • Department of Health and Aging expected to relax the restrictions on the provision of PET services 13
Slide 14: Macquarie University Hospital
Macquarie University Hospital For personal use only • 183 bed university hospital • 12 operating theatres • Specialising in Oncology and Neurology • Home of the Australian School of Advanced Medicine • Adjacent specialty clinic containing 18 specialist suites
Slide 15: Diagnostic Imaging
Diagnostic Imaging For personal use only PET • Joint venture with Alfred Health X‐Ray Solutions CT • Comprehensive suite of imaging modalities Cardiac CT • State of the art research platform MRI • Inpatient and outpatient services Ultra‐ sound • Foundation for regional growth SPECT 15
Slide 16: 2009 Financials
For personal use only 2009 Fi Financials i l 16
Slide 17: Profit & Loss
Profit & Loss For personal use only 9Net profit after tax increases 19% 2009 2008 • Technegas related sales $ $ revenue increased 2% CONTINUING OPERATIONS on prior period. Sales revenue 11,098,579 10,888,269 Finance revenue 93,186 49,377 • One time contribution b Other revenue 2,403,090 52,852 of Cl
Slide 18: Sales revenue - Segmental Review
Sales revenue ‐ Segmental Review For personal use only 9 Consolidated profit margins improve Patient Administration Sets (PAS) • PAS revenue down d 1.7% 1 7% to t $9.13 $9 13 m • PAS volumes down 2.6% • Sales margins consistent with 2008 Technegas • Generator G volumes l up 30% • Generator revenue u
Slide 19: Sales revenue - Half year comparison
Sales revenue Half year comparison For personal use only 9 Historical Trend – strong second half results continue 19
Slide 20: Balance Sheet
Balance Sheet For personal use only 9 Strong Net Asset Position • US$1.8m received from Balance Sheet Summary 2009 2008 settlement with $ $ Clinquest Inc Total Current Assets 12,169,793 12,443,583 Total Non-current Assets 7,474,618 5,519,687 Total Assets 19,644,411 , , 17,963,270 , , • Debt facility
Slide 21: Operating Cash flow
Operating Cash flow For personal use only 9 Cash flows from operating activities of $3.7m • The improvement in operating 2009 2008 cashh flows fl resulted lt d from f the th $ $ US$1.8m settlement with Operating activities 3,691,032 1,486,028 Clinquest Inc (offset by $0.8m Investing activities (3,09
Slide 22: Business Objectives 2010
For personal use only Business Objectives 2010 22
Slide 23: Business Deliverables - Technegas
Business Deliverables Technegas For personal use only New Drug Application (NDA) • Successful meeting held with FDA April 2010 • Protocol submission scheduled for June 2010 • Clinical trial commencement targeted Q4 2010 New Indications for Technegas • Currently in discussions with researchers and cl
Slide 24: Business Deliverables - PET Radiopharmaceuticals
Business Deliverables PET Radiopharmaceuticals For personal use only Macquarie i University i i Hospital i l (MUH) ( ) • Facility completed • Cyclotron y performance testingg completed p p • Radiation safety licenses received • TGA audit pending • Sales forecasted for Q3 2010 Expansion Opportunities
Slide 25: Business Deliverables - Diagnostic Imaging
Business Deliverables Diagnostic Imaging For personal use only Macquarie q Medical Imaging g g • $18m banking facility secured • Equipment delivered • Fit‐out completed May 2010 • First patients early June 2010 Expansion • Expansion opportunities currently under review 25
Slide 26: Conclusion
For personal use only C l i Conclusion 26
Slide 27: Cyclopharm business
Cyclopharm business For personal use only Cyclopharm ‐ helping save lives everyday! Technegas Radiopharmaceuticals Diagnostic Imaging Established in 1986 continues to Establishment of PET central Developing centres that provide generate revenue, profits and strong pharmacies to produce PET services
Slide 28: Question Time & Business
For personal use only Q ti Ti Question Time & B Business i 28
Slide 29: Proxy Summary
Proxy Summary For personal use only Resolution Business For* Against Abstain Proxy’s di discretion ti 1 Remuneration Report 103,535,671 56,090 252,744 544,372 2 Re-election of Mr Vanda 101,657,068 - 2,187,437 544,372 Russell Gould 3 Share Buy-back 103,465,346 145,701 233,458 544,372 4 Longg Term Inc